Xeno Transplants Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XENO research report →
Companywww.xenotransplants.com
Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine.
- CEO
- Elliot Lebowitz
- IPO
- 2006
- HQ
- Brookline, MA, US
Price Chart
Valuation
- Market Cap
- $4.04K
- P/E
- -0.03
- P/S
- 0.00
- P/B
- 0.01
- EV/EBITDA
- 0.22
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -68.64%
- ROIC
- 33.21%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-128,185 · -174.74%
- EPS
- $-0.00 · 61.00%
- Op Income
- $128.19K
- FCF YoY
- -1909.55%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -28.50
- Avg Volume
- 163
Get TickerSpark's AI analysis on XENO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our XENO Coverage
We haven't published any research on XENO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XENO Report →